BlackRock Fund Advisors’s KalVista Pharmaceuticals KALV Stock Holding History

BlackRock Fund Advisors’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$16K	Buy	2,274 +514	+29%	+$3.79K	﹤0.01%	3911
2016 Q3	$11K	Buy	1,760 +1,534	+679%	+$11.6K	﹤0.01%	3950
2016 Q2	$2K	Sell	226 -22,196	-99%	-$257K	﹤0.01%	4215
2016 Q1	$202K	Sell	22,422 -1,285	-5%	-$23K	﹤0.01%	3458
2015 Q4	$1.2M	Buy	23,707 +685	+3%	+$35.8K	﹤0.01%	3215
2015 Q3	$1.15M	Sell	23,022 -274	-1%	-$23.4K	﹤0.01%	3198
2015 Q2	$2.33M	Buy	+23,296	New	+$2.31M	﹤0.01%	3155

Other funds holding KALV

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

IBT

International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Quadrant Glendale, California $18M AUM 24.2% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

BlackRock Fund Advisors's KALV Position: Q4 2016 in Review

BlackRock Fund Advisors increased its KalVista Pharmaceuticals (KALV) stake by 29% in Q4 2016, buying an estimated $3.79K and bringing the position to 2,274 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #3911.

BlackRock Fund Advisors first reported a position in KALV in Q2 2015 and has held it in 7 quarters since. The position peaked at $2.33M in Q2 2015. 20 funds tracked by Wall St. Rank hold KALV as of Q4 2016.

BlackRock Fund Advisors held 2,274 shares of KalVista Pharmaceuticals worth $16K as of Q4 2016.
BlackRock Fund Advisors bought 514 KalVista Pharmaceuticals shares in Q4 2016, an estimated $3.79K.
KalVista Pharmaceuticals made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3911 holding.
BlackRock Fund Advisors first reported a position in KalVista Pharmaceuticals in Q2 2015 and has held it in 7 quarters since.
BlackRock Fund Advisors's KalVista Pharmaceuticals position peaked at $2.33M in Q2 2015.
20 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.